吉西他滨联合奥沙利铂治疗非霍奇金淋巴瘤疗效观察
The clinical observation on the effect of gemcitabine plus oxaliplatin in treatment of relapsed or refractory non-Hodgkin's lymphoma
摘要目的 观察吉西他滨联合奥沙利铂治疗复发性或难治性非霍奇金淋巴瘤(NHL)的临床疗效。方法 39例复发或难治性NHL患者,应用吉西他滨和奥沙利铂联合化疗3个周期以上后评价其疗效、不良反应,检测其血清乳酸脱氢酶(LDH)在治疗前后的浓度变化,并对患者进行随访。结果 39例患者中,完全缓解者11例,占28.21%;部分缓解者16例,占41.03%;无进展者7例,占17.95%;进展者5例,占12.82%;总有效率为69.23%。结论 吉西他滨和奥沙利铂联合化疗治疗复发性或难治性NHL患者安全有效。
更多相关知识
abstractsObjective To analyze the clinical efficacy of gemcitabine plus oxaliplatin in treatment of relapsed or refractory non-Hodgkin's lymphoma(NHL).Methods 39 cases with relapsed or refractory NHL were treated by gemcitabine and oxaliplatin combination chemotherapy. After three cycles, its efficacy and adverse reactions were observed. Serum lactate dehydrogenase(LDH) concentration was detected before and after treatment and all the patients were followed up. Results The rate CR was 11cases (28. 1% ), PR 16cases (41.03%), NC 7cases (17.95%),PD 5cases(12.82%).Thetotalresponserate(CR+PR) was 69. 23%. Conclusion Gemcitabineand oxaliplatin combination chemotherapy in treatment of patients with relapsed or refractory NHL was safe and effective.
More相关知识
- 浏览575
- 被引6
- 下载20

相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文